Article
Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Oct 2021
Akamatsu Hiroaki, Murakami Haruyasu, Harada Hideyuki, Shimizu Junichi, Hayashi Hidetoshi, Daga Haruko, Hasegawa Yoshikazu, Kim Young Hak, Kato Terufumi, Tokunaga Shoji, Nishimura Yasumasa, Yamamoto Nobuyuki, Nakagawa Kazuhiko
Abstract excerpt
INTRODUCTION: About 10% of patients with locally advanced NSCLC (LA-NSCLC) harbor EGFR mutation and recent reports suggested the declined benefit with an immune checkpoint inhibitor in this population. The attempt that introduces EGFR tyrosine kinase inhibitor into the treatment of LA-NSCLC with EGFR mutation has been warranted. METHODS: Chemotherapy-naive patients with unresectable LA-NSCLC with sensitive EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.